Biomarkers of Response

Better Predict Patient Response with Validated Predictive Biomarkers

In modern drug discovery and oncology diagnoses, biomarkers play an important role in the early detection of disease, prediction of susceptibility, and personalization of treatment.

At CrownBio, we are focused on discovering and validating PD, surrogate, and predictive biomarkers that can differentiate between responders and non-responders in a patient population.

Validate Antitumor Effects Against Predicted Human Targets

As part of our Translational Oncology program, CrownBio has developed Biomarkers of Response  Platform to understand the relationships between:

• Genes
• Protein expression
• Molecular interactions
• And activity

that define the fundamental components of a predictive biomarker, help clients to explain the mechanism of action of and profile resistance mechanisms to their particular treatment regimen.

Our Biomarkers of response leverages data from PDX mouse clinical trials, which utilize our highly predictive Solid Tumor PDX Collecion/Models and Liquid Tumor PDX Collection/Models. Our large diverse collection of PDX now covers 2,500 models and over 30 cancer types, providing growing panels of PDX with patient-relevant mutations for biomarker study.

Crown Biosciences Biomarkers of Response Helps You Differentiate Between Responders and Non-Responders in a Population

The Biomarkers of Response Platform spans a range of capabilities and analyses, from tissue collection to data analysis, and is helping to validate antitumor effects against predicted human targets.

Accelerate Candidate Success in the Clinic

Biomarkers of Response identifies biomarkers of response, improving clients understanding of their compound target population, and allowing the selection of appropriate models to accelerate their candidate success in the clinic.

Biomarkers are identified from PDX MCTs results via a range of techniques including:

• Whole genome profiling and data analysis
• Next generation genome sequencing
• Mutation analysis bioinformatics
• In vitro and in vivo PD marker identification
• Biomarker assay development and validation
• Quantitative western blot, FACS analysis
• Immunohistochemistry
• DNA sequencing